Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

por Abramson, Jeremy S., Johnston, Patrick B., Kamdar, Manali, Ibrahimi, Sami, Izutsu, Koji, Arnason, Jon, Glass, Bertram, Mutsaers, Pim, Lunning, Matthew, Braverman, Julia, Liu, Fei Fei, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Guo, Shien, Shi, Ling, Solomon, Scott R.
Publicado 2022

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

por Abramson, Jeremy S., Solomon, Scott R., Arnason, Jon, Johnston, Patrick B., Glass, Bertram, Bachanova, Veronika, Ibrahimi, Sami, Mielke, Stephan, Mutsaers, Pim, Hernandez-Ilizaliturri, Francisco, Izutsu, Koji, Morschhauser, Franck, Lunning, Matthew, Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro, Ogasawara, Ken, Kamdar, Manali
Publicado 2023